Wally R Smith

Dr. Wally R Smith

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in The Journal of Pain
Verified
Journal Article
Closed access
CDCarlton Dampier
Carlton Dampier
TPTonya M. Palermo
Tonya M. Palermo
DDDeepika S. Darbari
Deepika S. Darbari
KHKathryn Hassell
Kathryn Hassell
WSWally R Smith
Wally R Smith
WZWilliam Zempsky
William Zempsky

1 August 2021 in Value in Health
Verified
Journal Article
Closed access
DHDavid Holdford
David Holdford
NVNicholas Vendetti
Nicholas Vendetti
DSDaniel M. Sop
Daniel M. Sop
SJShirley Johnson
Shirley Johnson
WSWally R Smith
Wally R Smith

1 March 2019 in Southern Medical Journal
Verified
Journal Article
Closed access
WSWally R Smith
Wally R Smith
ISIndia Y. Sisler
India Y. Sisler
SJShirley Johnson
Shirley Johnson
TLThokozeni J. Lipato
Thokozeni J. Lipato
JNJennifer S. Newlin
Jennifer S. Newlin
KPKathryn Polak
Kathryn Polak
Objective: More effective transitions and transfers of young people with sickle cell disease (SCD) into the adult healthcare setting is a focus of both primary care and specialty care medical organizations. Effective transition and transfer requires six core elements: establishing a policy, tracking progress, administering transition readiness assessments, planning for adult care, transferring to...

12 December 2025 in Blood Advances
Verified
Journal Article
Open access
ASAkshay Sharma
Akshay Sharma
FLFranco Locatelli
Franco Locatelli
MBMonica Bhatia
Monica Bhatia
LMLyndsay Molinari
Lyndsay Molinari
MMMarkus Y. Mapara
Markus Y. Mapara
HFHaydar Frangoul
Haydar Frangoul
Severe sickle cell disease (SCD), an inherited blood disorder characterized by recurrent vaso-occlusive crises (VOCs), significantly impairs health-related quality of life (HRQoL). Exagamglogene autotemcel (exa-cel), a one-time, ex vivo CRISPR/Cas9 gene-edited cell therapy, eliminated VOCs in 97% of participants with severe SCD in the phase 3 CLIMB SCD-121 trial. Here, we describe changes in patient-reported outcomes (PROs) in 30 adults and 12 adolescents with ≥16 months follow-up. Adult PROs include EuroQol Quality of Life Scale–5 dimensions–5 levels of severity (EQ-5D-5L), Functional Assessment of Cancer Therapy Bone Marrow Transplant (FACT-BMT), Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me), and 11-point pain Numerical Rating Scale (NRS). In adolescents, EuroQol Quality of Life Scale–5 dimensions–youth (EQ-5D-Y), Pediatric Quality of Life Inventory (PedsQL), and pain NRS were used. Adult EQ-5D-5L US and UK healthy utility index and EQ visual analog scale (VAS) scores, which were lower than general population norm at baseline, substantially improved by month 6 after exa-cel infusion and were sustained through month 36, with similar improvements in FACT-General (FACT-G) total and bone marrow transplant subscale. All FACT-G (physical, social/family, emotional, functional well-being) and ASCQ-Me (emotional, social functioning, stiffness, sleep impact) subscales showed clinically meaningful improvement, including ASCQ-Me pain subscales (impact, episode frequency, severity), with substantial decreases in pain episode frequency by month 6. Mean pain NRS score decreased by month 6 and was sustained. Consistent with adults, adolescents had improvements in mean EQ-5D-Y VAS score, PedsQL score, and pain NRS. Exa-cel led to broad and clinically meaningful HRQoL benefits in adults and adolescents with SCD. The CLIMB SCD-121 and CLIMB-131 trials were registered at www.clinicaltrials.gov as #NCT03745287 and #NCT04208529, respectively.

23 May 2024 in Pain
Verified
Journal Article
Open access
AJAshna Jagtiani
Ashna Jagtiani
ECEric Chou
Eric Chou
SGScott Gillespie
Scott Gillespie
KLKatie Liu
Katie Liu
LKLakshmanan Krishnamurti
Lakshmanan Krishnamurti
NBNitya Bakshi
Nitya Bakshi
The US National Pain Strategy recommends identifying individuals with chronic pain (CP) who experience substantial restriction in work, social, or self-care activities as having high-impact chronic pain (HICP). High-impact chronic pain has not been examined among individuals with CP and sickle cell disease (SCD). We analyzed data from 63 individuals with SCD and CP who completed at least 5 months of pain diaries in the Pain in Sickle Cell Epidemiology Study (PiSCES). Forty-eight individuals met the definition for HICP, which was operationalized in this study as reporting pain interference on more than half of diary days. Compared with individuals without HICP, individuals with HICP experienced higher mean daily pain intensity, particularly on days without crises. They also experienced a greater proportion of days with pain, days with healthcare utilization, and days with home opioid use and higher levels of stress. They did not have a statistically significantly higher proportion of days with crises or experience higher mean daily pain intensity on days with crises. Individuals with HICP experienced worse physical functioning and worse physical health compared with those without HICP, controlling for mean pain intensity, age, sex, and education. The results of this study support that HICP is a severely affected subgroup of those with CP in SCD and is associated with greater pain burden and worse health outcomes. The findings from this study should be confirmed prospectively in a contemporary cohort of individuals with SCD.

9 November 2023 in Frontiers in Pain Research
Verified
Journal Article
Open access
WSWally R Smith
Wally R Smith
CVCecelia R. Valrie
Cecelia R. Valrie
CJCheedy Jaja
Cheedy Jaja
MKMartha O. Kenney
Martha O. Kenney
Sickle cell disease (SCD) is a prevalent and complex inherited pain disorder that can manifest as acute vaso-occlusive crises (VOC) and/or chronic pain. Despite their known risks, opioids are often prescribed routinely and indiscriminately in managing SCD pain, because it is so often severe and debilitating. Integrative medicine strategies, particularly non-opioid therapies, hold promise in safe and effective management of SCD pain. However, the lack of evidence-based methods for managing SCD pain hinders the widespread implementation of non-opioid therapies. In this review, we acknowledge that implementing personalized pain treatment strategies in SCD, which is a guideline-recommended strategy, is currently fraught with limitations. The full implementation of pharmacological and biobehavioral pain approaches targeting mechanistic pain pathways faces challenges due to limited knowledge and limited financial and personnel support. We recommend personalized medicine, pharmacogenomics, and integrative medicine as aspirational strategies for improving pain care in SCD. As an organizing model that is a comprehensive framework for classifying pain subphenotypes and mechanisms in SCD, and for guiding selection of specific strategies, we present evidence updating pain research pioneer Richard Melzack’s neuromatrix theory of pain. We advocate for using the updated neuromatrix model to subphenotype individuals with SCD, to better select personalized multimodal treatment strategies, and to identify research gaps fruitful for exploration. We present a fairly complete list of currently used pharmacologic and non-pharmacologic SCD pain therapies, classified by their mechanism of action and by their hypothesized targets in the updated neuromatrix model.